Axonis Therapeutics Secures $115M Series A to Advance Neuromedicine Pipeline
Boston, MA, October 30, 2024 (PRNewswire) -- Axonis Therapeutics raised $115 million in Series A funding to advance AXN-027 for epilepsy and pain treatment. Axonis will advance its oral KCC2 pipeline to treat neurological conditions.
Read full article here.
Comments